Literature DB >> 33639976

Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice.

Chao Shang1, Xinyu Zhuang1, He Zhang1, Yiquan Li2, Yilong Zhu2, Jing Lu3, Chenchen Ge3, Jianan Cong1, Tingyu Li1, Mingyao Tian4, Ningyi Jin5,6,7, Xiao Li8,9,10.   

Abstract

BACKGROUND: Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2 and broke out as a global pandemic in late 2019. The acidic pH environment of endosomes is believed to be essential for SARS-CoV-2 to be able to enter cells and begin replication. However, the clinical use of endosomal acidification inhibitors, typically chloroquine, has been controversial with this respect.
METHODS: In this study, RT-qPCR method was used to detect the SARS-CoV-2N gene to evaluate viral replication. The CCK-8 assay was also used to evaluate the cytotoxic effect of SARS-CoV-2. In situ hybridization was used to examine the distribution of the SARS-CoV-2 gene in lung tissues. Hematoxylin and eosin staining was also used to evaluate virus-associated pathological changes in lung tissues.
RESULTS: In this study, analysis showed that endosomal acidification inhibitors, including chloroquine, bafilomycin A1 and NH4CL, significantly reduced the viral yields of SARS-CoV-2 in Vero E6, Huh-7 and 293T-ACE2 cells. Chloroquine and bafilomycin A1 also improved the viability and proliferation of Vero E6 cells after SARS-CoV-2 infection. Moreover, in the hACE2 transgenic mice model of SARS-CoV-2 infection, chloroquine and bafilomycin A1 reduced viral replication in lung tissues and alleviated viral pneumonia with reduced inflammatory exudation and infiltration in peribronchiolar and perivascular tissues, as well as improved structures of alveolar septum and pulmonary alveoli.
CONCLUSIONS: Our research investigated the antiviral effects of endosomal acidification inhibitors against SARS-CoV-2 in several infection models and provides an experimental basis for further mechanistic studies and drug development.

Entities:  

Keywords:  Bafilomycin A1; Chloroquine; Endosomal acidification; SARS-CoV-2

Year:  2021        PMID: 33639976     DOI: 10.1186/s12985-021-01515-1

Source DB:  PubMed          Journal:  Virol J        ISSN: 1743-422X            Impact factor:   4.099


  19 in total

Review 1.  Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies.

Authors:  Sarah Mousavi; Shima Zare; Mahmoud Mirzaei; Awat Feizi
Journal:  Can J Infect Dis Med Microbiol       Date:  2022-09-25       Impact factor: 2.585

2.  Proper Selection of In Vitro Cell Model Affects the Characterization of the Neutralizing Antibody Response against SARS-CoV-2.

Authors:  Elena Criscuolo; Benedetta Giuliani; Davide Ferrari; Roberto Ferrarese; Roberta A Diotti; Massimo Clementi; Nicasio Mancini; Nicola Clementi
Journal:  Viruses       Date:  2022-06-07       Impact factor: 5.818

Review 3.  Comparison of Cell Fusions Induced by Influenza Virus and SARS-CoV-2.

Authors:  Chuyuan Zhang; Xinjie Meng; Hanjun Zhao
Journal:  Int J Mol Sci       Date:  2022-07-01       Impact factor: 6.208

Review 4.  The Mechanisms and Animal Models of SARS-CoV-2 Infection.

Authors:  Wenrui Jia; Juan Wang; Bao Sun; Jiecan Zhou; Yamin Shi; Zheng Zhou
Journal:  Front Cell Dev Biol       Date:  2021-04-27

5.  Low-Dose Fluvoxamine Modulates Endocytic Trafficking of SARS-CoV-2 Spike Protein: A Potential Mechanism for Anti-COVID-19 Protection by Antidepressants.

Authors:  Oleg O Glebov
Journal:  Front Pharmacol       Date:  2021-12-16       Impact factor: 5.810

Review 6.  SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19.

Authors:  Evgenii Gusev; Alexey Sarapultsev; Liliya Solomatina; Valeriy Chereshnev
Journal:  Int J Mol Sci       Date:  2022-02-02       Impact factor: 5.923

Review 7.  Kidney Injury in COVID-19: Epidemiology, Molecular Mechanisms and Potential Therapeutic Targets.

Authors:  J Pedro Teixeira; Sharon Barone; Kamyar Zahedi; Manoocher Soleimani
Journal:  Int J Mol Sci       Date:  2022-02-17       Impact factor: 5.923

Review 8.  Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics.

Authors:  Lennox Chitsike; Penelope Duerksen-Hughes
Journal:  Virol J       Date:  2021-07-23       Impact factor: 4.099

9.  SARS-CoV-2 Causes Mitochondrial Dysfunction and Mitophagy Impairment.

Authors:  Chao Shang; Zirui Liu; Yilong Zhu; Jing Lu; Chenchen Ge; Cuiling Zhang; Nan Li; Ningyi Jin; Yiquan Li; Mingyao Tian; Xiao Li
Journal:  Front Microbiol       Date:  2022-01-06       Impact factor: 5.640

10.  In silico screening of potent inhibitors against COVID-19 key targets from a library of FDA-approved drugs.

Authors:  Mohammad A Elmorsy; Ahmed M El-Baz; Nashwa H Mohamed; Rafa Almeer; Mohamed M Abdel-Daim; Galal Yahya
Journal:  Environ Sci Pollut Res Int       Date:  2021-09-25       Impact factor: 4.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.